title: [Safety and immunogenecity of a vaccine of polyssacharide Vi from Salmonella typhi in Cuban youths].
abstract: A randomized, controlled and double-blind study was conducted in young adults aged 18-20 aimed at evaluating the reactogenecity and immunogenecity of vaz-TyVi, a vaccine of polyssacharide Vi from Salmonella typhi. They were distributed into 3 groups: immunized with a dose of Vax-TyVi (Finlay Institute), TYPHIM Vi (Pasteur-Mérieux) or vax-TET (tetanic toxoid). Serum samples were taken before and 21 days after immunization. The immunogenecity was evaluated in 323 volunteers by an indirect ELISA. The seroconversion of those receiving vax-TyVi was 81.97% and 65.05 % for TYPHIM Vi. The postvaccine mean geometric titers were 7.41 U/mL (5.92-9.27 U/mL) and 5.41 U/mL (4.35-6.72 U/mL), respectively. The seroconversion with vax-TET was 0%. The reactogenecity of both polysaccharide vaccines was low. It was concluded that the immunogenecity of vax-TyVi was not lower than that of TYPHIM Vi and that its reactogenecity was similar.
authors.affiliation: Instituto "Carlos J. Finlay", Ciudad de La Habana, Cuba. ochoa@finlay.edu.cu
authors.forename: Rolando Felipe Ochoa
authors.initials: RF
authors.lastname: Azze
authors.forename: Idalia Morelia Baró
authors.initials: IM
authors.lastname: Suárez
authors.forename: Juan Carlos Martínez
authors.initials: JC
authors.lastname: Rodríguez
authors.forename: Mayelin Mirabal
authors.initials: MM
authors.lastname: Sosa
authors.forename: Marlene Isabel Armesto
authors.initials: MI
authors.lastname: del Río
authors.forename: Francisco Domínguez
authors.initials: FD
authors.lastname: Alvarez
mesh_terms: D000293:Adolescent; D000328:Adult; D003462:Cuba; D004311:Double-Blind Method; D006801:Humans; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D022562:Salmonella Vaccines / Q000276:immunology*
chemical_list: D011135:Polysaccharides, Bacterial; D022562:Salmonella Vaccines; C054154:capsular polysaccharide, Salmonella